Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial
Titel:
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial
Auteur:
Jastorff, Archana Gymnopoulou, Efi Salas, Jose Merrall, Elizabeth Buntinx, Erik Martin, Charlotte Askling, Helena H. Schenkenberger, Isabelle Yuste, Angela Cano Smith, William Sotolongo, Roberto Von Engelhardt, Charlotte Bastian, Arangassery Rosemary Comeaux, Christy Ligtenberg, Nynke Callendret, Benoit Heijnen, Esther